• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Latest News

Arcutis Submits sNDA for Roflumilast Foam to FDA for Scalp and Body Psoriasis
Arcutis Submits sNDA for Roflumilast Foam to FDA for Scalp and Body Psoriasis

July 23rd 2024

The submission to the FDA is supported by positive results from the ARRECTOR phase 3 trial.

Offering an Insurance Package to Retain and Reward Employees: What Dermatologists Should Know
Offering an Insurance Package to Retain and Reward Employees: What Dermatologists Should Know

July 23rd 2024

Expert Reflections: Mentors Elevating Careers
Expert Reflections: Mentors Elevating Careers

July 22nd 2024

Evaluating the Efficacy and Perception of HS Treatment Options
Evaluating the Efficacy and Perception of HS Treatment Options

July 22nd 2024

Oral Dimethyl Fumarate Improves All Disease Classification Criteria in Plaque Psoriasis
Oral Dimethyl Fumarate Improves All Disease Classification Criteria in Plaque Psoriasis

July 22nd 2024

Meet the 2024 Quarterly Editor in Chiefs
Reimbursement Success for Laser Treatments
Breakthroughs in Pediatric Atopic Dermatitis
Subscribe Now for Free - eNL
Explore Our Conference Coverage
3
Subscribe for Free - Print
Stay Informed!
Don't miss the latest in dermatology news

Conference Coverage

View All
Hematologic Safety of Ruxolitinib Cream in Children with Atopic Dermatitis
Hematologic Safety of Ruxolitinib Cream in Children with Atopic Dermatitis

July 19th 2024

Advanced Practice Providers Share Insights at the 2024 Society for Pediatric Dermatology Annual Meeting
Advanced Practice Providers Share Insights at the 2024 Society for Pediatric Dermatology Annual Meeting

July 19th 2024

Phase 3 Ruxolitinib Study Shows Higher Rates of Adolescent Repigmentation
Phase 3 Ruxolitinib Study Shows Higher Rates of Adolescent Repigmentation

July 16th 2024

Recap: 2024 Society for Pediatric Dermatology Annual Meeting
Recap: 2024 Society for Pediatric Dermatology Annual Meeting

July 15th 2024

Latest Videos

All News

© 2024 MJH Life Sciences

All rights reserved.